-
Proteinase K: From DNA Prep to Translational Insight
2026-08-27
Proteinase K is more than a routine digestion reagent. This thought-leadership guide explains how its broad-spectrum serine protease activity supports high-integrity DNA workflows, enables mechanistic studies of protein cargo, and can strengthen translational investigations inspired by recent Candida albicans extracellular-vesicle research.
-
Chondrocyte-Targeted NAC Nanoparticles in Osteoarthritis
2026-08-27
This 2025 Small Science study develops chondroitin sulfate-modified PLGA nanoparticles for sustained, chondrocyte-targeted delivery of N-acetylcysteine in osteoarthritis. The formulation preserves glutathione and GPX4 activity, suppresses ferroptosis under mechanical stress, and protects cartilage more effectively than free NAC or nontargeted nanoparticles in a murine model.
-
Dabigatran Etexilate: Translational Thrombin Strategy
2026-08-26
A mechanistic and translational guide to using Dabigatran etexilate as a direct thrombin inhibitor, from target engagement and coagulation assays to atrial fibrillation research and in vivo validation.
-
METTL16–SENP3–LTF Drives HCC Ferroptosis Resistance
2026-08-26
Wang et al. identify a METTL16–SENP3–LTF signaling axis that suppresses iron-dependent lipid peroxidation and promotes hepatocellular carcinoma progression. By combining epitranscriptomic, protein-turnover, genetic, organoid, animal, and clinical analyses, the study connects m6A-regulated RNA stability with iron sequestration and suggests a route for ferroptosis sensitization.
-
Stiripentol: Applied LDH Inhibitor Workflows
2026-08-25
Stiripentol offers a research-ready route to perturb LDH1/LDH5-dependent lactate flux in epilepsy, metabolic, and immune-cell assays. This guide turns its mechanism and solubility profile into practical workflows for astrocyte-neuron lactate shuttle studies, lactate measurements, and histone lactylation experiments.
-
CKI 7 dihydrochloride: Reliable CK1 Assays
2026-08-25
This scenario-driven guide explains how CKI 7 dihydrochloride, SKU B4936, can support controlled Casein kinase 1 inhibition studies in viability, proliferation, apoptosis, Wnt, circadian, and cancer biology workflows. It covers experimental controls, solution preparation, interpretation, and practical product-selection criteria without overstating evidence.
-
Reserpine (N1867): Practical Lab Workflow
2026-08-24
Reserpine (SKU N1867) provides a defined, high-purity research compound for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and assay controls; the material is for research use only and is not intended for diagnostic, clinical, or veterinary applications.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike Binding
2026-08-24
The reference study shows that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike protein binding to host receptors, with effects determined by peptide length, receptor identity, and tyrosine modification. Its antibody-based binding experiments identify angiotensin (2–7) and related fragments as useful probes for investigating how renin-angiotensin signaling intersects with viral receptor engagement, while also highlighting important limits on biological interpretation.
-
Brefeldin A: From Trafficking Block to ER Stress
2026-08-23
Brefeldin A is more than a vesicle transport inhibitor: it is a temporal perturbation tool for connecting ER-to-Golgi traffic, protein quality control, and cancer-cell fate. This guide explains how to design and interpret BFA experiments using ER-stress adaptation as the central decision point.
-
Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor
2026-08-22
The reference study identified Merbromin as a selective mixed-type inhibitor of the SARS-CoV-2 3CLpro protease through activity-based screening, enzyme kinetics, binding analysis, and molecular docking. Its findings provide a biochemical starting point for inhibitor design while emphasizing the difference between target-level inhibition and demonstrated antiviral efficacy.
-
SINE-Induced XPO1 Degradation by Allostery
2026-08-22
The reference study shows that SINE inhibitors do more than block XPO1-mediated nuclear export: they remodel XPO1 to recruit the CRL substrate receptor ASB8 and trigger ubiquitin-dependent degradation. Cryo-EM, cellular turnover assays, and mechanistic validation define an allosteric degradation pathway that may explain how synthetic XPO1 inhibitors exploit a native cellular response.
-
Phosbind Biotin for Reliable Phosphorylation Analysis
2026-08-21
Phos binding reagent (Phosbind) Biotin, SKU F4001, supports sequence-independent Western Blot detection of phosphorylated proteins through dinuclear metal complex phosphate binding. This scenario-driven guide explains assay compatibility, reagent handling, interpretation, and practical vendor-selection considerations for researchers studying viability, proliferation, cytotoxicity, and signaling.
-
Microsecond Pulsed Fields and Mitochondrial Cardiac Ablation
2026-08-20
The reference study defines exposure conditions under which microsecond pulsed electric fields produce reliable cardiomyocyte ablation and links the effect to mitochondrial disruption and apoptosis-associated signaling. Its combination of dose-response testing, transcriptomics, ultrastructural imaging, and mouse validation provides a mechanistic framework for interpreting pulsed-field ablation beyond irreversible electroporation alone.
-
Nilotinib (AMN-107): From Kinase Control to Immune Reset
2026-08-20
Nilotinib (AMN-107) is best known for precise BCR-ABL pathway control, but emerging evidence positions it as a valuable tool for studying tumor immune visibility. This thought-leadership guide connects chronic myeloid leukemia research, gastrointestinal stromal tumor research, and colorectal cancer immunobiology through a practical translational framework.
-
Separating Growth Inhibition from Cancer Cell Death
2026-08-19
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing proliferative arrest from cell killing, including their differing magnitudes and temporal relationships, which can improve interpretation of in vitro drug screens.